Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 25, 2008
- Wholesalers' SGA Expense Ratio Drops to below 7% for the First Time
August 25, 2008
- Eliminating Losses due to Invoice Prices Higher than Sales Prices Is Not Easy: Mr Matsutani
August 25, 2008
- SSP Aims at Growth Rate 2 Points Above Industry Average: President Hatori
August 25, 2008
- Price Settlement Rate Reaches 53% as of July 31: Mediceo Paltac
August 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 25, 2008
- Price Settlement Rates as of End of June Similar to Those Reported 2 Years Ago
August 25, 2008
- 13th ACCJ Media Lectures
August 25, 2008
- Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
August 25, 2008
- Market Price Surveys to Focus on Generics
August 25, 2008
- Pfizer Starts Detailing Macugen for AMD
August 25, 2008
- R&D NEWS IN BRIEF
August 25, 2008
- Top Management Changes Made within 2 Months Announced by Ono
August 25, 2008
- Development of New Drugs for AMD Stimulated
August 25, 2008
- Eisai Licenses Bendamustine from SymBio
August 25, 2008
- R&D NEWS IN BRIEF
August 11, 2008
- MSNW Supports Rational Drug Pricing
August 11, 2008
- GENERICS NEWS IN BRIEF
August 11, 2008
- JPMA Members Improving Distribution Business Practices: Mr Negi
August 11, 2008
- JRCS Considers Joint Purchase of Generics
August 11, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…